Friday Morning the company announced on Friday April 16th, Eugene C. Somoza, MD, PhD will present a paper he authored along with Charles Gorodetzky, MD, PhD, Douglas Winship and Peggy Somoza, entitled: "A Multi-Site, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Vigabatrin (VGB) for Treating Cocaine Dependence" at the American Society of Addiction Medicine's 41st Annual Medical-Scientific Conference in San Francisco, CA. Dr. Somoza was the Coordinating Principal Investigator for the trial and will discuss data from Catalyst's U.S. Phase II trial evaluating CPP-109, Catalyst's form of Vigabatrin, to treat cocaine addiction.
Radient Pharmaceuticals Corp. (AMEX:RPC) is trading at $2.30 up $0.83 or 56% on heavy volume of 16.6M
This stock has been on an absolute tear as it has soared nearly 1,000% in the last 5 days. Just 5 days ago stock was trading at a mere $0.25. More news came out of Radient today as it announced today it anticipates prospective purchasers or financiers will complete due diligence for RPC's China-based subsidiary Jade Pharmaceutical, Inc. (JPI) by the end of May 2010. RPC expects JPI will be contractually positioned to move forward with the completion of a sale or financing by the end of the third quarter 2010.
No comments:
Post a Comment